Author(s): Ajay K. Gupta, Sanmati K. Jain

Email(s): sanmatijain72@yahoo.co.in

DOI: 10.52711/0974-360X.2022.00783   

Address: Ajay K. Gupta, Sanmati K. Jain*
Department of Pharmacy, Guru Ghasidas Vishwavidyalaya, Bilaspur 495009, Chhattisgarh, India.
*Corresponding Author

Published In:   Volume - 15,      Issue - 10,     Year - 2022


ABSTRACT:
Prostate cancer is the second leading cause of cancer death in men. Androgen receptor (AR) inhibitor is one of class of drug used in this disease. AR inhibitors include bicalutamide, flutamide, nilutamide, apalutamide, darolutamide and enzalutamide. Among them Flutamide is being selected because it causes liver damage on long term use that can be serious or life-threatening. In the current study, Bioisosteric approach has been used for amide group in the Flutamide molecule in order to develop the newer analogues having lesser side effects like liver damage, which is major cause of the drug withdrawal. Therefore amide bioisosteres of it are designed using bioisosteric approach in order to develop relatively safe compounds. A wide variety of amide bioisosteres of Flutamide were generated i.e., Ester, Amide, Reverse amide, Urea, Carbamate, Reverse Ester, Thioamide, 1,2,4-oxadiazole, Sulphonamide, Ketone etc., using MolOpt. Pharmacokinetic and toxicity (ADMET) properties of newly designed analogues are computed by using ADMElab2.0 and pkCSM. Druglikeness and Drugscore was calculated by PEO. All the ligands obey the Lipinski rule and had good human intestinal absorption. Flutamide is used as the reference drug. The results indicate that compound 002 and 022 showed NR-AR binding (desirable in Prostate cancer) and QED value (measure of drug likeness; > 0.67) comparable with the standard drug. These compounds showed low toxicity [human hepatotoxicity (H-HT) and drug induced liver injury (DILI)] as compared to Flutamide. This study could lead to the further development of potent AR antagonist for the treatment of prostate cancer.


Cite this article:
Ajay K. Gupta, Sanmati K. Jain. Design of Amide bioisosteres of Flutamide as Novel Androgen Receptor Antagonist in Prostate Cancer Therapy. Research Journal of Pharmacy and Technology 2022; 15(10):4667-6. doi: 10.52711/0974-360X.2022.00783

Cite(Electronic):
Ajay K. Gupta, Sanmati K. Jain. Design of Amide bioisosteres of Flutamide as Novel Androgen Receptor Antagonist in Prostate Cancer Therapy. Research Journal of Pharmacy and Technology 2022; 15(10):4667-6. doi: 10.52711/0974-360X.2022.00783   Available on: https://rjptonline.org/AbstractView.aspx?PID=2022-15-10-56


REFERENCES:
1.    Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71:7–33. doi: 10.3322/caac.21654.
2.    Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019; 10(2):63-89. doi: 10.14740/wjon1191.
3.    Fang H, Tong W, Branham WS, Moland CL, Dial SL, Hong H, Qian Xie, Perkins R, Owens W, Sheehan DM. Study of 202 Natural, Synthetic, and Environmental Chemicals for Binding to the Androgen Receptor. Chem. Res. Toxicol. 2003; 16:1338-1358. doi: 10.1021/tx030011g.
4.    Soderholm AA, Lehtovuori PT, Nyronen TH. Three-Dimensional Structure-Activity Relationships of Nonsteroidal Ligands in Complex with Androgen Receptor Ligand-Binding Domain. J. Med. Chem. 2005; 48: 917-925. doi: 10.1021/jm0495879.
5.    Sastry PSRK. Prostate Cancer at alarming stage?. Research J. Pharmacology and Pharmacodynamics. 2013; 5(6): 376-377.
6.    Kumari S, Carmona AV, Tiwari AK, Trippier PC, Amide Bond Bioisosteres: Strategies, Synthesis, and Successes. J. Med. Chem. 2020; 63:12290−12358. https://doi.org/10.1021/acs.jmedchem.0c00530.
7.    MolOpt software (In silico Bioisosteric Replacement System). Available:https://xundrug.cn/molopt.
8.    ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Guoli Xiong, Zhenxing Wu, Jiacai Yi, Li Fu, Zhijiang Yang, Changyu Hsieh, Mingzhu Yin, Xiangxiang Zeng, Chengkun Wu, Xiang Chen, Tingjun Hou, Dongsheng Cao, Nucleic Acids Res, 2021, 49, W5-W14. PMID:33893803. (https://admetmesh.scbdd.com).
9.    pkCSM: predicting small-molecule pharmacokinetic properties using graph-based signatures Douglas E. V. Pires, Tom L. Blundell, David B. Ascher, Journal of Medicinal Chemistry, 58 (9), p. 4066–4072, 2015.  (http://biosig.unimelb.edu.au/pkcsm/)
10.    OSIRIS Property Explorer (peo). Available: https://openmolecules.org/propertyexplorer/applet.html
11.    Karavadi B and Martina V, In-silico Analysis of Inhibitors Related to Aggressive Behavior in Human Beings. Research J. Pharm. and Tech. 2018; 11(4): 1436-1441.
12.    Reddy SC, Reddy SKG, Mahto MK, Kunala P and Kanth CR, In-silico Design and Discovery of Some Novel Ache Inhibitors for Treatment of Alzheimer's Disorder. Research J. Pharm. and Tech. 2012; 5(3): 425.
13.    Karavadi B and Shivashankari S, Computational study on receptors related to aggressive conduct. Research J. Pharm. and Tech. 2018; 11(5): 1729-1733.
14.    Nisha, H. and B. Karavadi, Computational analysis to identify the drug targets and their lead molecules in pancreatic cancer. Research J. Pharm. and Tech. 2017; 10(6): 1708.
15.    Ray NM, Singh R, Singh J, Bhati S and Kaushik V, Computational screening of Thiohydantoin Derivatives for antitumor activity. Research J. Pharm. and Tech. 2020; 13(2): 795-800. doi: 10.5958/0974-360X.2020.00150.X
16.    Zein AK, Faten S, Mohammad K. Design and In-Silico ADMET Analysis of new Benzopyrane-derived Pim-1 Inhibitors. Research J. Pharm. and Tech. 2019; 12(11):5413-5423. doi: 10.5958/0974-360X.2019.00939.9
17.    Hardjono S, Widiandani T, Purwanto BT, Nasyanka AL, Molecular Docking of N-benzoyl-N'-(4-fluorophenyl) thiourea Derivatives as Anticancer Drug Candidate and Their ADMET prediction. Research J. Pharm. and Tech. 2019; 12(5):2160-2166. doi: 10.5958/0974-360X.2019.00359.7
18.    Chelamalla R and Makula A, Molecular docking studies and ADMET predictions of pyrimidine coumarin scaffolds as potential IDO inhibitors. Asian J. Research in Chemistry, 2017; 10(3): p. 331-340.
19.    Subramnian G, Rajagopal K, Sherin S, Molecular Docking Studies, In-silico ADMET Screening of Some Novel Thiazolidine Substituted Oxadiazoles as Sirtuin 3 Activators Targeting Parkinson’s Disease. Research J. Pharm. and Tech 2020; 13(6): 2708-2714. doi: 10.5958/0974-360X.2020.00482.5
20.    Bhati S, Kaushik V, Singh J. In Silico Identification of Piperazine Linked Thiohydantoin Derivatives as Novel Androgen Antagonist in Prostate Cancer Treatment. Int J Pept Res Ther. 2019; 25: 845-860. DOI: 10.1007/s10989-018-9734-5.




Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

1.3
2021CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available